Parabilis Medicines, Inc. (PBLS) vs Tarsus Pharmaceuticals, Inc. (TARS)
A side-by-side comparison of Parabilis Medicines, Inc. and Tarsus Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
PBLS
Parabilis Medicines, Inc.
$28.86HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
TARS
Tarsus Pharmaceuticals, Inc.
$74.11HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — PBLS vs TARS
growth of $100 · dividends reinvested · last 1yPBLS +47.7% (+47.7%/yr)TARS +25.6% (+25.6%/yr)PBLS compounded faster over this window
PBLS TARS
PBLS vs TARS: by the numbers
- •PBLS is the larger company ($3.36B vs $3.19B market cap).
- •Both run net losses; PBLS's is the smaller (0.00% vs -7.67% net margin).
Metrics side by side
Valuation
| Metric | PBLS | TARS |
|---|---|---|
| P/S ratio | N/A | 5.26 |
| P/B ratio | 3.21 | 9.20 |
| FCF yield | N/A | 1.93% |
Profitability
| Metric | PBLS | TARS |
|---|---|---|
| Gross margin | 0.00% | 90.59% |
| Operating margin | 0.00% | -8.00% |
| Net margin | 0.00% | -7.67% |
| ROE | N/A | -13.40% |
| ROIC | -409.85% | -11.15% |
Growth (annualized)
| Metric | PBLS | TARS |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 61.36% |
| Total return CAGR (5Y) | N/A | 28.33% |
Go deeper
Dig into the metrics
Parabilis Medicines ROETarsus Pharmaceuticals ROEParabilis Medicines operating marginTarsus Pharmaceuticals operating marginParabilis Medicines revenue growthTarsus Pharmaceuticals revenue growthParabilis Medicines free cash flowTarsus Pharmaceuticals free cash flow
Parabilis Medicines & Tarsus Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.